01
019170.KO Shin Poong Pharm.Co.Ltd.
- Market cap
- KRW 441B
- P/E
- -
- P/B
- 1.63x
- ROE
- -5.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 019170.KO undervalued?
Graham numberThe Graham number of Shin Poong Pharm.Co.Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shin Poong Pharm.Co.Ltd. fundamental analysis
No fundamental analysis for Shin Poong Pharm.Co.Ltd. yet.
Shin Poong Pharm.Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shin Poong Pharm.Co.Ltd.
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder…
Full company profileShin Poong Pharm.Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shin Poong Pharm.Co.Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 194B | 185B | 187B | 190B | 198B | 189B | 209B | 200B | 221B | 235B | 237B |
| Gross Profit | 87.9B | 80.1B | 75.9B | 76.2B | 76.5B | 77.4B | 78.0B | 80.3B | 81.8B | 103B | 96.8B |
| Operating Income | 9.57B | 7.81B | 7.75B | 5.60B | 7.85B | -14.3B | 78.0B | -47.4B | -17.0B | 14.3B | -16.8B |
| EBITDA | - | 16.0B | 20.8B | 23.5B | 23.5B | 3.89B | -21.9B | -39.8B | -27.1M | 22.5B | -558M |
| Net Income | -18.6B | 905M | 2.80B | 5.32B | 5.00B | -11.6B | -35.4B | -57.3B | -15.4B | 8.83B | -15.3B |
| EPS | - | 19 | 58 | 111 | 102 | -235 | -718 | -1,163 | -312 | 171 | -296 |
| Balance Sheet | |||||||||||
| Total Assets | 416B | 386B | 381B | 380B | 487B | 393B | 362B | 350B | 342B | 352B | 367B |
| Total Liabilities | 200B | 176B | 173B | 171B | 113B | 38.0B | 30.8B | 79.3B | 84.0B | 81.7B | 88.5B |
| Shareholders' Equity | 217B | 210B | 206B | 208B | 373B | 353B | 330B | 270B | 257B | 270B | 277B |
| Cash & Short-term Investments | 16.1B | 19.4B | 37.2B | 23.4B | 55.8B | 27.6B | 41.7B | 43.8B | 42.0B | 47.4B | 48.1B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.0B | 10.1B | 32.1B | 19.4B | 20.1B | -71.0B | -26.4B | -24.8B | -15.2B | 17.3B | 10.4B |
| Capital Expenditure | 1.50B | 3.08B | 1.79B | 12.1B | 2.65B | 4.42B | 6.23B | 15.0B | 6.09B | 3.99B | 4.71B |
| Free Cash Flow | - | 6.59B | 30.2B | 5.17B | 16.9B | -76.6B | -32.7B | -39.8B | -21.2B | 13.3B | 5.72B |
| Ratios | |||||||||||
| ROE | -8.6% | 0.4% | 1.4% | 2.6% | 1.3% | -3.3% | -10.7% | -21.3% | -6.0% | 3.3% | -5.5% |
| ROA | -4.5% | 0.2% | 0.7% | 1.4% | 1.0% | -3.0% | -9.8% | -16.4% | -4.5% | 2.5% | -4.2% |
| Net Profit Margin | -9.6% | 0.5% | 1.5% | 2.8% | 2.5% | -6.1% | -16.9% | -28.6% | -7.0% | 3.8% | -6.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shin Poong Pharm.Co.Ltd. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 29, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | KRW 5.16B | 105 | - |
| 2020 | KRW 5.16B | 105 | 103.1% |
| 2019 | KRW 5.16B | 107 | 96.8% |
| 2018 | KRW 5.16B | 107 | 183.9% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.040008:1 on Dec 29, 2014.
Who owns Shin Poong Pharm.Co.Ltd.
- Insiders 31.99%
- Institutions 2.57%
- Public & others 65.44%
- Shares outstanding 51.7M
- Free float 36.4M
Shin Poong Pharm.Co.Ltd. company profile
- Company name
- Shin Poong Pharm.Co.Ltd.
- Ticker
- 019170.KO
- ISIN
- KR7019170000
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 656
- Fiscal year end
- December
- Address
- 161, Yeoksam-ro, Seoul, South Korea, 06246
- Phone
- 82 2 2189 3400
- Website
- shinpoong.co.kr
About Shin Poong Pharm.Co.Ltd.
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products. In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.
Shin Poong Pharm.Co.Ltd. management
3- Mr. Jei-Man RyuCEO & Inside Director · born 1956
- InIl JeongHead of Financial Management Division
- Mr. JooYoung SungMD & Inside Director · born 1965